Pennsylvania Adds Anxiety & Tourette Syndrome as “Serious Medical Conditions” under the PA Medical Marijuana Act

Fox Rothschild LLP
Contact

Fox Rothschild LLP

Back in May, I blogged about a recommendation from the Pennsylvania Medical Marijuana Advisory Board to add Anxiety and Tourette Syndrome as “serious medical conditions” covered under the Pennsylvania Medical Marijuana Act. At the time, the Department of Health (DOH) stated a decision on whether to formally approve this recommendation would be made by this Summer, and the Department kept this deadline. On July 11, 2019, the Secretary of DOH, Dr. Rachel Levine, announced that the two will be approved as qualifying conditions effective July 20, 2019.

The PA Medical Marijuana Act originally identified 17 “Serious Medical Conditions,” and in 2018, the Advisory Board expanded that list to include four additional conditions. This announcement brings the total number of qualifying conditions to 23 (which can be found here).

In May, Dr. Levine noted that she wanted to review medical research in anticipation of making a final decision. The official press release from the DOH stated that the medical literature supported the decision to approve these conditions, but added a few caveats from Dr. Levine regarding the use of medical marijuana to treat Anxiety and Tourette Syndrome:

  • “marijuana is not first line treatment and should not replace traditional therapies [like counseling and therapy] but should be used in conjunction with them, when recommended by a physician”
  • “medical marijuana with low THC and high CBD content are more effective for treatment of anxiety disorders and is recommended for short-term use”
  • “medical marijuana is not recommended to treat children and adolescents with anxiety disorders, as their brains are still developing”
  • “pregnant women with any of the approved serious medical conditions should not use medical marijuana as the impacts on the fetus are unknown”

Dr. Levine provided additional information about the announcement and her decision via her Twitter account:

Today I announced that effective no later than July 20, anxiety disorders and Tourette syndrome will be approved serious medical conditions in PA's medical marijuana program, bringing the total list of approved conditions to 23. pic.twitter.com/dnBqY4CFPX

— Dr. Rachel Levine (@SecretaryLevine) July 11, 2019

After a careful review of the medical literature available about these conditions, I have decided to approve this recommendation. Patients should consult with their health care provider to see if medical marijuana will be beneficial for them. https://t.co/97BSDvtFy4

— Dr. Rachel Levine (@SecretaryLevine) July 11, 2019

As always, patients, caregivers, doctors, and other members of the public can find out more about Pennsylvania’s Medical Marijuana Program through the PA DOH website.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Fox Rothschild LLP | Attorney Advertising

Written by:

Fox Rothschild LLP
Contact
more
less

Fox Rothschild LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide